RNF212B

Summary

RNF212B (ring finger protein 212B, HGNC:20438) is a protein-coding gene on chromosome 14q11.2, encoding E3 ubiquitin-protein ligase RNF212B (A8MTL3). Ubiquitin E3 ligase that acts as a crucial factor for crossing-over (CO) formation during meiosis.

Predicted to enable SUMO transferase activity and ubiquitin protein ligase activity. Predicted to be involved in chiasma assembly and protein ubiquitination. Predicted to be located in chromosome. Predicted to be active in synaptonemal complex.

Source: NCBI Gene 100507650 — RefSeq curated summary.

At a glance

• Gene–disease (curated): infertility disorder (Moderate, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 2 total — 1 likely-pathogenic
• MANE Select transcript: NM_001282322

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20438
Approved symbol	RNF212B
Name	ring finger protein 212B
Location	14q11.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000215277
Ensembl biotype	protein_coding
OMIM	621020
Entrez	100507650

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 7 protein_coding, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000399905, ENST00000399910, ENST00000430154, ENST00000463881, ENST00000470456, ENST00000470818, ENST00000492355, ENST00000492621, ENST00000498441, ENST00000689421, ENST00000913744, ENST00000951077

RefSeq mRNA: 2 — MANE Select: NM_001282322 NM_001282322, NM_001370218

CCDS: CCDS61401

Canonical transcript exons

ENST00000430154 — 15 exons

Exon	Start	End
ENSE00001540738	23262665	23262711
ENSE00001540739	23260659	23260687
ENSE00001540740	23259884	23259944
ENSE00001540744	23258549	23258664
ENSE00001540746	23244322	23244396
ENSE00001540748	23243256	23243308
ENSE00002438168	23240345	23240445
ENSE00003491107	23270600	23270661
ENSE00003524994	23272823	23273477
ENSE00003540623	23268924	23268963
ENSE00003629807	23262928	23262970
ENSE00003635109	23269863	23269960
ENSE00003687268	23264174	23264234
ENSE00003787941	23264623	23264671
ENSE00003932268	23237936	23238055

Expression profiles

Bgee: expression breadth ubiquitous, 157 present calls, max score 92.27.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1144 / max 26.9472, expressed in 35 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
138884	0.1144	35

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
kidney epithelium	UBERON:0004819	92.27	gold quality
sperm	CL:0000019	91.52	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.05	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.58	gold quality
right testis	UBERON:0004534	78.03	gold quality
left testis	UBERON:0004533	77.65	gold quality
testis	UBERON:0000473	76.34	gold quality
adult organism	UBERON:0007023	72.61	gold quality
adult mammalian kidney	UBERON:0000082	72.41	gold quality
kidney	UBERON:0002113	71.26	gold quality
pancreatic ductal cell	CL:0002079	70.98	silver quality
islet of Langerhans	UBERON:0000006	68.21	gold quality
cortex of kidney	UBERON:0001225	66.90	gold quality
tibialis anterior	UBERON:0001385	66.54	silver quality
metanephros cortex	UBERON:0010533	63.34	gold quality
calcaneal tendon	UBERON:0003701	63.25	gold quality
monocyte	CL:0000576	63.09	gold quality
leukocyte	CL:0000738	62.89	gold quality
stromal cell of endometrium	CL:0002255	62.25	gold quality
ileal mucosa	UBERON:0000331	61.82	silver quality
left lobe of thyroid gland	UBERON:0001120	61.63	gold quality
mucosa of stomach	UBERON:0001199	61.49	gold quality
sural nerve	UBERON:0015488	61.09	gold quality
right lobe of thyroid gland	UBERON:0001119	60.76	gold quality
thyroid gland	UBERON:0002046	60.54	gold quality
right coronary artery	UBERON:0001625	59.61	gold quality
right uterine tube	UBERON:0001302	59.53	gold quality
pancreas	UBERON:0001264	58.41	gold quality
metanephros	UBERON:0000081	58.40	gold quality
tibial nerve	UBERON:0001323	57.30	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-131882	yes	2066.65
E-CURD-119	yes	1985.40
E-ANND-3	yes	5.67

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

91 targeting RNF212B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-6755-5P	99.95	65.59	464
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220

Literature-anchored findings (GeneRIF, showing 1)

• A pathogenic variant in the uncharacterized RNF212B gene results in severe aneuploidy male infertility and repeated IVF failure. (PMID:37124137)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	rnf212b	ENSDARG00000093723
mus_musculus	Rnf212b	ENSMUSG00000112858
rattus_norvegicus	Rnf212b	ENSRNOG00000066673
drosophila_melanogaster	narya	FBGN0031018
drosophila_melanogaster	nenya	FBGN0051053
caenorhabditis_elegans	zhp-3	WBGENE00006976
caenorhabditis_elegans	zhp-2	WBGENE00008387
caenorhabditis_elegans		WBGENE00012678
caenorhabditis_elegans	zhp-1	WBGENE00018867

Paralogs (1): RNF212 (ENSG00000178222)

Protein

Protein identifiers

E3 ubiquitin-protein ligase RNF212B — A8MTL3 (reviewed: A8MTL3)

Alternative names: RING finger protein 212B

All UniProt accessions (5): A0A8I5QKV8, A8MTL3, A8MVE6, G3V2N7, H0YJB3

UniProt curated annotations — full annotation on UniProt →

Function. Ubiquitin E3 ligase that acts as a crucial factor for crossing-over (CO) formation during meiosis. Essential for normal prophase I progression and for ensuring appropriate CO designation in meiosis. Recruits key components of the cross-over machinery either directly ou indirectly, leading to the activation of the MutL-gamma complex. The function of RNF212B in CO designation is dependent on its catalytic activity.

Subunit / interactions. Homodimer.

Subcellular location. Chromosome.

Post-translational modifications. Autoubiquitinated.

Pathway. Protein modification; protein ubiquitination.

RefSeq proteins (2): NP_001269251, NP_001357147 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR017907	Znf_RING_CS	Conserved_site
IPR042123	Zip3/RNF212-like	Family

UniProt features (11 total): compositionally biased region 4, sequence conflict 2, chain 1, zinc finger region 1, region of interest 1, coiled-coil region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A8MTL3-F1	67.10	0.34

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 69 (showing top): GOBP_MEIOTIC_CHROMOSOME_SEGREGATION, GOBP_CHROMOSOME_ORGANIZATION, GOBP_ORGANELLE_FISSION, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_CHROMOSOME_ORGANIZATION_INVOLVED_IN_MEIOTIC_CELL_CYCLE, GOBP_HOMOLOGOUS_CHROMOSOME_SEGREGATION, GOBP_MEIOTIC_CELL_CYCLE_PROCESS, GOBP_HOMOLOGOUS_CHROMOSOME_PAIRING_AT_MEIOSIS, GOBP_NUCLEAR_CHROMOSOME_SEGREGATION, GOBP_MEIOTIC_CELL_CYCLE, GOBP_CELL_CYCLE_PROCESS, GOBP_DNA_METABOLIC_PROCESS, GOMF_ACYLTRANSFERASE_ACTIVITY, GOBP_DNA_RECOMBINATION, GOMF_SUMO_TRANSFERASE_ACTIVITY

GO Biological Process (5): homologous chromosome pairing at meiosis (GO:0007129), protein ubiquitination (GO:0016567), chiasma assembly (GO:0051026), reciprocal meiotic recombination (GO:0007131), meiotic cell cycle (GO:0051321)

GO Molecular Function (5): zinc ion binding (GO:0008270), SUMO transferase activity (GO:0019789), ubiquitin protein ligase activity (GO:0061630), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (2): synaptonemal complex (GO:0000795), chromosome (GO:0005694)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
meiotic cell cycle process	2
homologous chromosome segregation	1
chromosome organization involved in meiotic cell cycle	1
protein modification by small protein conjugation	1
homologous chromosome pairing at meiosis	1
reciprocal meiotic recombination	1
cellular component assembly	1
meiosis I	1
reciprocal homologous recombination	1
cell cycle	1
sexual reproduction	1
reproductive process	1
meiotic nuclear division	1
transition metal ion binding	1
ubiquitin-like protein transferase activity	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
catalytic activity	1
cation binding	1
synaptonemal structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

192 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RNF212B	HFM1	A2PYH4	626
RNF212B	OR10G3	Q8NGC4	615
RNF212B	OR10G2	Q8NGC3	613
RNF212B	MSH4	O15457	605
RNF212B	REC114	Q7Z4M0	591
RNF212B	REC8	O95072	573
RNF212B	TEX11	Q8IYF3	557
RNF212B	SPO11	Q9Y5K1	520
RNF212B	MLH3	P49751	470
RNF212B	TOX4	O94842	456
RNF212B	PRDM9	Q9NQV7	447
RNF212B	SUPT16H	Q9Y5B9	446
RNF212B	CPLX1	O14810	446
RNF212B	CCNB1IP1	Q9NPC3	419
RNF212B	SHOC1	Q5VXU9	411

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0A1W2P884, A0M8S4, A0M8T5, A5PLL1, A8MTL3, B9EJA2, D3Z423, F1QZ88, F6TQD1, O54916, O60296, P0C6C1, Q00PJ1, Q07DV1, Q07DX4, Q07E15, Q07E28, Q07E41, Q09YG9, Q09YI1, Q09YK4, Q108T9, Q13625, Q2IBB2, Q2IBD4, Q2IBE6, Q2IBF7, Q2QLA2, Q2QLB3, Q2QLF8, Q2VUH7, Q3UIL6, Q3UUF8, Q53HC0, Q5PQ89, Q5RBV9, Q5RJ80, Q5SZL2, Q6IQ23, Q6P2H3

Diamond homologs: A8MTL3, C6KRL6, D3Z423, Q495C1, Q5RBV9, F6TQD1, Q8MYP1

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	RNF212B	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	0
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3062225	NM_001282322.3(RNF212B):c.448C>T (p.Arg150Ter)	Likely pathogenic

SpliceAI

2406 predictions. Top by Δscore:

Variant	Effect	Δscore
14:23230160:G:GT	donor_gain	1.0000
14:23243254:A:AG	acceptor_gain	1.0000
14:23243255:G:GG	acceptor_gain	1.0000
14:23243255:GAA:G	acceptor_gain	1.0000
14:23243255:GAAAA:G	acceptor_gain	1.0000
14:23243309:G:GG	donor_gain	1.0000
14:23244320:A:AG	acceptor_gain	1.0000
14:23244321:G:GG	acceptor_gain	1.0000
14:23244321:GCT:G	acceptor_gain	1.0000
14:23185491:G:GG	donor_gain	0.9900
14:23240343:A:AG	acceptor_gain	0.9900
14:23240344:G:GG	acceptor_gain	0.9900
14:23243250:TCCCA:T	acceptor_loss	0.9900
14:23243251:CCCA:C	acceptor_loss	0.9900
14:23243252:CCA:C	acceptor_loss	0.9900
14:23243254:AGAA:A	acceptor_loss	0.9900
14:23243255:G:T	acceptor_loss	0.9900
14:23243255:GA:G	acceptor_gain	0.9900
14:23243255:GAAA:G	acceptor_gain	0.9900
14:23244318:GTA:G	acceptor_loss	0.9900
14:23244319:TA:T	acceptor_loss	0.9900
14:23244321:GCTGA:G	acceptor_gain	0.9900
14:23244392:CTCAG:C	donor_loss	0.9900
14:23244393:TCAGG:T	donor_loss	0.9900
14:23244394:CAG:C	donor_loss	0.9900
14:23244395:AGGTA:A	donor_loss	0.9900
14:23244396:G:GC	donor_loss	0.9900
14:23244397:G:GA	donor_loss	0.9900
14:23244398:T:A	donor_loss	0.9900
14:23264164:C:G	acceptor_gain	0.9900

AlphaMissense

1948 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:23258558:T:C	F80L	0.997
14:23258560:C:A	F80L	0.997
14:23258560:C:G	F80L	0.997
14:23240361:T:C	C6R	0.995
14:23258559:T:C	F80S	0.995
14:23240401:T:A	V19D	0.994
14:23240424:T:C	C27R	0.994
14:23240361:T:A	C6S	0.993
14:23240362:G:A	C6Y	0.993
14:23240362:G:C	C6S	0.993
14:23240363:C:G	C6W	0.993
14:23240352:T:A	W3R	0.992
14:23240352:T:C	W3R	0.992
14:23240370:T:A	C9S	0.992
14:23240371:G:C	C9S	0.992
14:23240409:T:C	C22R	0.992
14:23243261:T:C	C36R	0.992
14:23258583:T:C	L88P	0.992
14:23240362:G:T	C6F	0.991
14:23240370:T:C	C9R	0.991
14:23258562:A:C	Q81P	0.991
14:23240410:G:A	C22Y	0.990
14:23244347:T:C	F60S	0.990
14:23240409:T:A	C22S	0.988
14:23240410:G:C	C22S	0.988
14:23240425:G:A	C27Y	0.988
14:23240433:T:C	C30R	0.988
14:23243270:T:C	C39R	0.988
14:23258580:T:C	L87P	0.988
14:23240358:C:G	H5D	0.987

dbSNP variants (sampled 300 via entrez): RS1000048658 (14:23231795 A>G), RS1000055152 (14:23194197 G>T), RS1000155947 (14:23190976 G>C), RS1000165876 (14:23190734 G>A,C), RS1000168744 (14:23273942 A>G), RS1000177844 (14:23268277 C>T), RS1000244086 (14:23234920 A>G,T), RS1000247811 (14:23220599 G>A), RS1000317047 (14:23266706 C>T), RS1000327002 (14:23192660 A>G,T), RS1000349060 (14:23186317 T>A), RS1000349551 (14:23196491 G>A), RS1000367548 (14:23226330 T>A,G), RS1000384240 (14:23244246 T>A), RS1000404372 (14:23261617 C>G,T)

Disease associations

OMIM: gene MIM:621020 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
infertility disorder	Moderate	Autosomal recessive

Mondo (2): female infertility (MONDO:0021124), infertility disorder (MONDO:0005047)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST010244_81	Triglyceride levels	2.000000e-09
GCST90002402_226	Platelet count	8.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0004309	platelet count

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D007246	Infertility	C12.100.750
D007247	Infertility, Female	C12.050.351.500.498; C12.100.250.498; C12.100.750.350

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs7141505	RNF212B, SLC7A8		0.00	0

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
benzo(e)pyrene	decreases methylation	1
ferrous chloride	decreases expression	1
aflatoxin B2	decreases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
Benzo(a)pyrene	affects methylation	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment	1
Methapyrilene	decreases methylation	1

Clinical trials (associated diseases)

207 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01388907	PHASE4	COMPLETED	Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery
NCT01430650	PHASE4	COMPLETED	Endometrial Priming for Embryo Transfer
NCT02607319	PHASE4	COMPLETED	Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure
NCT03169166	PHASE4	COMPLETED	The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
NCT03177122	PHASE4	UNKNOWN	Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
NCT03477929	PHASE4	UNKNOWN	Cetrorelix and Ganirelix Flexible Protocol for (IVF)
NCT03619707	PHASE4	COMPLETED	Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles
NCT03846544	PHASE4	COMPLETED	Double Pick up in Poor Prognosis Women
NCT05725512	PHASE4	RECRUITING	Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages
NCT06195163	PHASE4	NOT_YET_RECRUITING	TRAP Study: Testosterone for Androgen Receptor Polymorphism
NCT06763926	PHASE4	NOT_YET_RECRUITING	Intranasal Nafarelin For Triggering Oocyte Maturation
NCT01577472	PHASE4	COMPLETED	Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol
NCT01791751	PHASE4	COMPLETED	Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles
NCT02070198	PHASE4	UNKNOWN	Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF
NCT02328924	PHASE4	COMPLETED	There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols?
NCT03057574	PHASE4	UNKNOWN	Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI
NCT05197374	PHASE4	COMPLETED	Effect of Estradiol Pretreatment on Antagonist ICSI Cycles
NCT05281341	PHASE4	COMPLETED	Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)
NCT05286554	PHASE4	COMPLETED	Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
NCT05608590	PHASE4	UNKNOWN	What is the Best Moment for Performing an HSG in Women With a Unfulfilled Childwish
NCT05753098	PHASE4	COMPLETED	Effect of Sildenafil Citrate Compared to Estrogen as Adjuvant Therapy for Unexplained Infertility
NCT06434233	PHASE4	RECRUITING	Opioid Use After Laparoscopic Salpingectomy
NCT06684951	PHASE4	COMPLETED	Effects of Intrauterine Flushing With Human Chorionic Gonadotropin on ICSI Outcome
NCT06921395	PHASE4	RECRUITING	Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).
NCT00749853	PHASE3	SUSPENDED	Efficacy of Ovarian Stimulation Based on FSHR Genotype Status
NCT03238092	PHASE3	UNKNOWN	Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort
NCT03803228	PHASE3	COMPLETED	Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders
NCT01850030	PHASE3	COMPLETED	A Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization
NCT02175498	PHASE3	COMPLETED	Effectiveness of Homeopathic Treatment in Female Infertility
NCT02491437	PHASE3	COMPLETED	A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)
NCT03429621	PHASE3	COMPLETED	Effect of Simethicone on Reducing Bowel Interference During Tubal Resection
NCT03542331	PHASE3	UNKNOWN	Endometrial Effects of Lipiodol
NCT03767569	PHASE3	UNKNOWN	Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients
NCT03862586	PHASE3	COMPLETED	NAC Effect on Hox Genes Expressions in RIF
NCT05266924	PHASE3	UNKNOWN	Recombinant Follicle-stimulating Hormone in Treatment for Infertility
NCT05460858	PHASE3	UNKNOWN	NAC Effect on Infertile Women With Endometrioma
NCT04701034	PHASE2	COMPLETED	Intravenous Immunoglobulin and Prednisolone for RPL After ART.
NCT04850261	PHASE2	WITHDRAWN	Injection Free IVF
NCT06997900	PHASE2	RECRUITING	Menopur And Rekovelle Combination Study Version 2.0
NCT01354886	PHASE1	COMPLETED	Single Dose FSH-GEX™ in Healthy Volunteers